https://scholars.lib.ntu.edu.tw/handle/123456789/396195
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | JIA-FENG WU | en_US |
dc.contributor.author | YU-CHUN CHIU | en_US |
dc.contributor.author | KAI-CHI CHANG | en_US |
dc.contributor.author | HUEY-LING CHEN | en_US |
dc.contributor.author | YEN-HSUAN NI | en_US |
dc.contributor.author | HONG-YUAN HSU | en_US |
dc.contributor.author | MEI-HWEI CHANG | en_US |
dc.contributor.author | Chen, Huey-Ling | en_US |
dc.contributor.author | Yen-Hsuan Ni | en_US |
dc.contributor.author | Ni, Yen-Hsuan | en_US |
dc.contributor.author | Hsu, Hong-Yuan | en_US |
dc.contributor.author | Chang, Mei-Hwei | en_US |
dc.contributor.author | Chen, Chi-Ling | en_US |
dc.contributor.author | 倪衍玄 | en_US |
dc.contributor.author | 陳惠玲 | en_US |
dc.contributor.author | 張美惠 | en_US |
dc.contributor.author | 許宏遠 | en_US |
dc.contributor.author | 吳嘉? | en_US |
dc.contributor.author | 張凱琪 | en_US |
dc.contributor.author | 邱郁淳 | en_US |
dc.creator | Chen, Chi-Ling;Hsu, Hong-Yuan;Chang, Mei-Hwei;Chiu, Yu-Chun;Chang, Kai-Chi;Ni, Yen-Hsuan;Chen, Huey-Ling;許宏遠;邱郁淳;張凱琪;吳嘉?;張美惠;Wu, Jia-Feng;陳惠玲;倪衍玄;HONG-YUAN HSU;MEI-HWEI CHANG;HUEY-LING CHEN;JIA-FENG WU;Yen-Hsuan Ni | - |
dc.date.accessioned | 2018-09-10T15:32:25Z | - |
dc.date.available | 2018-09-10T15:32:25Z | - |
dc.date.issued | 2016-01 | - |
dc.identifier.uri | http://europepmc.org/abstract/med/26389515 | - |
dc.identifier.uri | http://scholars.lib.ntu.edu.tw/handle/123456789/396195 | - |
dc.description.abstract | Hepatitis B e antigen (HBeAg)-negative hepatitis is a clinical indicator of poor outcome for chronic hepatitis B viral (HBV) infection. This long-term prospective cohort study aimed to elucidate the predictors of developing HBeAg-negative hepatitis in chronic HBV-infected subjects followed from childhood to adulthood. We followed 434 HBeAg-positive chronic HBV-infected patients from a median age of 7.22 years (interquartile range 4.31-10.21 years). Spontaneous HBeAg seroconversion occurred in 359 subjects at a median age of 13.93 years (interquartile range 8.76-20.59 years), and 75 subjects developed HBeAg seroconversion after antiviral therapy. These patients were followed for a median of 14.40 years (interquartile range 6.14-22.02 years) after HBeAg seroconversion. Clinical data were analyzed to delineate the predictors of developing HBeAg-negative hepatitis. The HBV basal core promoter and precore/core gene sequences were also evaluated in subjects with and without HBeAg-negative hepatitis. The overall annual incidence of HBeAg-negative hepatitis was 0.37% (95% confidence internal 0.35-0.39) in spontaneous HBeAg seroconverters. The overall annual incidence of HBeAg-negative hepatitis increased to 2.64% in lamivudine-treated subjects but did not increase in those treated with interferon-alpha (0.58%). Male gender (hazard ratio = 3.15), HBV genotype C (hazard ratio = 4.40), HBeAg seroconversion after 18 years of age (hazard ratio = 2.46), and lamivudine therapy prior to HBeAg seroconversion (hazard ratio = 1.42) were predictors of HBeAg-negative hepatitis in HBeAg seroconverters (P < 0.05). HBeAg-negative hepatitis subjects carried more A1762T/G1764A, C2063A, and A2131C HBV gene mutations than those without HBeAg-negative hepatitis. Conclusions: HBeAg seroconversion during childhood predicts a lower risk of HBeAg-negative hepatitis in later life. Interferon-alpha therapy may be an effective antiviral therapy beneficial in chronic HBV-infected children with severe inflammation that facilitates HBeAg seroconversion in earlier life. ? 2016 by the American Association for the Study of Liver Diseases. | - |
dc.language | en | en |
dc.source | AH | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | alpha interferon; entecavir; hepatitis B(e) antigen; lamivudine; antivirus agent; hepatitis B(e) antigen; adolescent; adult; adulthood; antiviral therapy; Article; child; childhood; chronic hepatitis B; cohort analysis; controlled study; disease severity; drug efficacy; female; gender; gene mutation; gene sequence; Hepatitis B virus; Hepatitis B virus genotype B; Hepatitis B virus genotype C; human; incidence; major clinical study; male; nonhuman; priority journal; prospective study; risk assessment; seroconversion; age; blood; follow up; Hepatitis B, Chronic; immunology; risk factor; young adult; Adolescent; Age Factors; Antiviral Agents; Child; Cohort Studies; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Prospective Studies; Risk Factors; Seroconversion; Young Adult | - |
dc.title | Predictors of hepatitis B e antigen-negative hepatitis in chronic hepatitis B virus-infected patients from childhood to adulthood. | - |
dc.type | journal article | en |
dc.identifier.doi | 10.1002/hep.28222 | - |
item.openairetype | journal article | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Pediatrics | - |
crisitem.author.dept | Pediatrics-NTUH | - |
crisitem.author.dept | Pediatrics | - |
crisitem.author.dept | Medical Education-NTUH | - |
crisitem.author.dept | Pediatrics-NTUH | - |
crisitem.author.dept | Medical Education and Bioethics | - |
crisitem.author.dept | Pediatrics | - |
crisitem.author.dept | Pediatrics-NTUH | - |
crisitem.author.dept | Medical Education and Bioethics | - |
crisitem.author.dept | Pediatrics-NTUH | - |
crisitem.author.dept | Pediatrics | - |
crisitem.author.dept | Pediatrics | - |
crisitem.author.dept | Pediatrics-NTUH | - |
crisitem.author.dept | Medical Education and Bioethics | - |
crisitem.author.dept | Pediatrics-NTUH | - |
crisitem.author.dept | Pediatrics-NTUH | - |
crisitem.author.dept | Pediatrics | - |
crisitem.author.orcid | 0000-0001-6343-1658 | - |
crisitem.author.orcid | 0000-0001-5714-6914 | - |
crisitem.author.orcid | 0000-0002-9720-3810 | - |
crisitem.author.orcid | 0000-0002-4074-5838 | - |
crisitem.author.orcid | 0000-0002-1158-5249 | - |
crisitem.author.orcid | 0000-0002-5720-4835 | - |
crisitem.author.orcid | 0000-0002-3648-9261 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 醫學教育暨生醫倫理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。